IGFBP-6, an IGFBP family member that can increase the half-life of circulatory insulin-like growth factors (IGFs), is a serum biomarker associated with poor prognosis in lung cancer and immune cell regulation (Cai et al., 2020; Sueoka et al., 2000). Here, IGFBP6 is linked to lung carcinoma.